Radiological and Clinical Features and Outcomes of Patients with Primary Pulmonary Salivary Gland-Type Tumors
Table 1
Clinical features of SGT.
Variable
No. of patients (%)
$
All patients
EMC
MEC
ACC
Age (years)
41 ± 16
43
35 ± 15
48 ± 16
0.038
Sex
0.285
Male
14 (43.8)
0
9 (56.3)
5 (33.3)
Female
18 (56.3)
1
7 (43.7)
10 (66.7)
Clinical symptom
Cough
17 (53.1)
0
10 (62.5)
7 (46.7)
0.479
Dyspnea
13 (40.6)
1
4 (25)
8 (53.3)
0.285
Chest pain
5 (15.6)
0
5 (31.3)
0 (0)
0.043
Hoarseness
1(3.1)
0
0(0)
1(6.7)
1.000
Hemoptysis
2 (6.3)
0
2 (12.5)
0 (0)
1.000
Blood-stained sputum
1 (3.1)
0
0 (0)
1 (6.7)
1.000
Asymptomatic
3 (9.4)
0
2 (12.5)
1 (6.7)
1.000
Dysphagia
2 (6.3)
0
0 (0)
2 (14.3)
1.000
Smoker
1.000
No
30 (93.8)
1
16 (100)
13 (86.7)
Yes
2 (6.3)
0
0 (0)
2 (13.3)
TNM stage
I
22 (68.8)
1
11 (68.8)
10 (66.7)
1.000
II
4 (12.5)
0
3 (18.8)
1 (6.7)
1.000
III
4 (12.5)
0
1 (6.3)
3 (20)
0.333
IV
2 (12.5)
0
1 (6.3)
1 (6.7)
1.000
Treatment
0
Surgical
24 (75)
1
13 (81.2)
10 (66.7)
0.433
Tracheal resection
12 (37.5)
1
3 (23.1)
8 (80)
0.066
Lobectomy
11 (34.4)
0
9 (69.2)
2 (20)
0.023
Wedge lobectomy
1 (3.1)
0
1 (7.8)
0 (0)
1.000
Adjuvant therapy
No
10 (31.3)
1
8 (50)
1 (6.7)
0.015
Chemotherapy
4 (12.5)
0
2 (12.5)
2 (13.3)
1.000
Radiotherapy
18 (56.3)
0
6 (40)
12 (75)
0.029
Resection margin
0.019
Negative
17 (53.1)
1
12 (92.3)
4 (40)
Positive
7 (21.9)
0
1 (7.7)
6 (60)
MEC, mucoepidermoid carcinoma; ACC, adenoid cystic carcinoma; TNM, tumor-node-metastasis. $ values for comparisons between MEC and ACC for each variable.
